Person: SALMAN, ANDAÇ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SALMAN
First Name
ANDAÇ
Name
50 results
Search Results
Now showing 1 - 10 of 50
Publication Open Access Nodular mucinosis of the breast: A rare entity(MARMARA UNIV, FAC MEDICINE, 2018-06-05) SALMAN, ANDAÇ; Salman, Andac; Cinel, Leyla; Turkoz, Huseyin Kemal; Akbas, Gamze; Ergun, TulinNodular mucinosis of the breast (NMB) is an uncommon disease involving the nipple-areolar region. It usually presents with asymptomatic, subcutaneous masses with indolent growth in women. Here, we report a 43-year-old man presented with a subcutaneous growth on the left nipple. Histopathological examination confirmed the diagnosis of NMB. We report our patient in order to point out this rare disease and think that the recognition of this entity is important for both clinicians and pathologists.Publication Open Access Erlotinib induced ectropion following papulopustular rash(SPECJALISCI DERMATOLODZY, 2015-06-30) SALMAN, ANDAÇ; Salman, Andac; Cerman, Eren; Seckin, Dilek; Kanitez, MetinBackground: Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR). Main observations: A 79-year-old developed bilateral ectropion after he received erlotinib treatment for lung adenocarcinoma. The ectropion completely resolved with symptomatic treatment without any modification in erlotinib therapy. Conclusions: EGFR inhibitors are frequently associated with a variety of mucocutaneous adverse events. Ocular toxicity associated with these agents has been reported rarely. We present this case to underline the importance of recognition of newly reported cutaneous and ocular adverse events of targeted therapies.Publication Metadata only Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres(2021) SALMAN, ANDAÇ; Can, P. K.; Salman, A.; Hoşgören-Tekin, S.; Kocatürk, E.Publication Metadata only What determines the treatment persistence in paediatric psoriasis?(WILEY, 2021) SALMAN, ANDAÇ; Salman, A.Publication Open Access Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic: Insights from Google Trends(WILEY, 2021-03) SALMAN, ANDAÇ; Esen-Salman, Kubra; Akin-cakici, Ozlem; Kardes, Sinan; Salman, AndacCoronavirus disease 2019 (COVID-19) pandemic had substantial effect both on daily life and medical practice. Internet data have been used to analyze the trends in public interest in various medical conditions and treatments. The aim of this study is to analyze the public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic. Google Trends was queried for a total of 120 dermatological search queries. Three periods of 2020 ([March 15-May 9], [May 10-July 4], and [July 5-October 31]) were compared with the previous 4 years (2016-2019). A significantly decreased interest in skin cancers and certain dermatologic conditions (eg, pityriasis rosea and scabies) was observed throughout the study period. Whereas a significant increase of interest in dry skin, hair shedding, oily hair, atopic dermatitis, and hand eczema was detected during the study. An initial decrease in interest was followed by a significant increase for acne, comedones, melasma, rosacea, botox, dermaroller, and peeling. The study demonstrated a significant impact of the COVID-19 pandemic on the public interest in dermatology. The present results would help to create healthcare policies and information sources, which can meet the public demand. The reasons for the observed trends and their effect on patient outcomes might be of interest for future studies.Publication Open Access Phacomatosis pigmentokeratotica associated with unilateral toe walking due to short achilles tendon(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020) SALMAN, ANDAÇ; Salman, Andac; Yucelten, Ayse Deniz; Cakici, Ozlem Akin; Unver, OlcayPhacomatosis pigmentokeratotica (PPK) is characterized by the co-occurrence of speckled lentiginous nevus (nevus spilus) and an organoid nevus with or without extracutaneous involvement. The extracutaneous manifestations may vary widely with musculoskeletal, neurologic, ocular, and vascular findings. The PPK is also associated with an increased risk of cutaneous or extracutaneous tumors. Therefore, the patients with PPK should be followed up regularly for possible malignant transformation. Here, we report a 5-year-old boy with PPK associated with toe walking due to short Achilles tendon, which was not previously reported, to our knowledge.Publication Metadata only Autoimmune progesterone dermatitis mimicking fixed drug eruption(2017) SALMAN, ANDAÇ; Salman, Andac; Ergun, TulinPublication Open Access Symmetrical drug-related intertriginous and flexural exanthema-like eruption: An addition to the spectrum of coronavirus disease 2019-related cutaneous findings(2022-11-01) SALMAN, ANDAÇ; Çakıcı Ö. A. , GUDER S., SALMAN A., Ergun T.Publication Metadata only Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data(WILEY, 2021) SALMAN, ANDAÇ; Salman, Andac; Aktas, Meryem; Sengun, Ozlem AptiOmalizumab is a well-established treatment option in chronic spontaneous urticaria unresponsive to antihistamines at standard or higher doses. However, characteristics of the remission and relapse following the withdrawal of omalizumab remain largely unknown. We aimed to define the characteristics of remission in CSU following omalizumab with gradually lengthened dosing intervals in this retrospective study of 102 patients who were treated with at least 5 doses of omalizumab between 2015 and 2020. Of 102 patients, 70 (68.6%) showed a CR to omalizumab at standard doses. Omalizumab could be discontinued in 47 of 70 patients using gradually lengthened dosing intervals. Following a mean follow-up duration of 12.2 months, 25 (58.1%) patients were still in remission while 18 (41.9%) had relapse (Follow-up data were not available in 4 patients). The relapses were unresponsive to antihistamines in 14 patients (77.7%), however, retreatment with omalizumab led to complete control of symptoms. The patients younger than 40 were more likely to relapse. Despite the need for comparison with fixed-dosing intervals in larger, prospective studies, the results of this study imply that omalizumab with gradually extended dosing intervals might provide a long duration of remission in CSU.Publication Metadata only Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test(WILEY, 2019) SALMAN, ANDAÇ; Salman, Andac; Yucelten, Deniz; Cakici, Ozlem Akin; Kadayifci, Eda KepenekliAcute generalized exanthematous pustulosis (AGEP) is seen uncommonly in children and sometimes shows atypical clinical features in this population. Patch testing can be used effectively in children for the confirmation of the culprit drug in cases of multiple drug use. Here, we report a rare, pediatric case of ceftriaxone-induced AGEP confirmed by patch testing with subsequent recurrence of the skin eruption.